Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial.

Gabriel Rinnerthaler; Simon Peter Gampenrieder; Hubert Hackl; Markus Steiner; Claudia Monzo-Fuentes; Thomas Melchardt; Teresa Magnes; Florian Huemer; Theresa Westphal; Clemens Hufnagl; Cornelia Hauser-Kronberger; Alexander Egle; Richard Greil

doi:10.3390/jcm9061663

Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial.

Gabriel Rinnerthaler^* (First author)
, Simon Peter Gampenrieder (First author)
, Hubert Hackl
, Markus Steiner (Co-author)
, Claudia Monzo-Fuentes
, Thomas Melchardt (Co-author)
, Teresa Magnes (Co-author)
, Florian Huemer (Co-author)
, Theresa Westphal (Co-author)
, Clemens Hufnagl (Co-author)
, Cornelia Hauser-Kronberger (Co-author)
, Alexander Egle (Co-author)
, Richard Greil (Last author)

^*Corresponding author for this work

Research output: Contribution to journal › Original Article › peer-review

8 Citations (Web of Science)

Original language	English
Journal	Journal of Clinical Medicine
Volume	9
Issue number	6
DOIs	https://doi.org/10.3390/jcm9061663
Publication status	Published - 2020

Keywords

PACLITAXEL PLUS BEVACIZUMAB
PROGRESSION-FREE SURVIVAL
1ST-LINE BEVACIZUMAB
GROWTH-FACTOR
THERAPY
HYPERTENSION
CHEMOTHERAPY
MICRORNAS
SURROGATE

Access to Document

10.3390/jcm9061663

Cite this

Rinnerthaler, G., Gampenrieder, S. P., Hackl, H., Steiner, M., Monzo-Fuentes, C., Melchardt, T., Magnes, T., Huemer, F., Westphal, T., Hufnagl, C., Hauser-Kronberger, C., Egle, A., & Greil, R. (2020). Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial. Journal of Clinical Medicine, 9(6). https://doi.org/10.3390/jcm9061663

@article{faf08673843f425dbf9531f6433de66d,

title = "Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial.",

keywords = "PACLITAXEL PLUS BEVACIZUMAB, PROGRESSION-FREE SURVIVAL, 1ST-LINE BEVACIZUMAB, GROWTH-FACTOR, THERAPY, HYPERTENSION, CHEMOTHERAPY, MICRORNAS, SURROGATE",

author = "Gabriel Rinnerthaler and Gampenrieder, \{Simon Peter\} and Hubert Hackl and Markus Steiner and Claudia Monzo-Fuentes and Thomas Melchardt and Teresa Magnes and Florian Huemer and Theresa Westphal and Clemens Hufnagl and Cornelia Hauser-Kronberger and Alexander Egle and Richard Greil",

note = "Rinnerhtaler; Gampenrieder; Steiner; Monzo-Fuentes; Melchardt; Magnes; Huemer; Westphal; Hufnagl; Egle; Greil: Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Department of Internal Medicine III with Haematology, Salzburg Cancer Research Institute, Oncologic Center Salzburg, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria; Hauser-Kronberger: Department of Pathology, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria",

year = "2020",

doi = "10.3390/jcm9061663",

language = "English",

volume = "9",

journal = "Journal of Clinical Medicine",

issn = "2077-0383",

publisher = "MDPI",

number = "6",

}

Rinnerthaler, G , Gampenrieder, SP, Hackl, H, Steiner, M, Monzo-Fuentes, C, Melchardt, T , Magnes, T , Huemer, F, Westphal, T, Hufnagl, C, Hauser-Kronberger, C, Egle, A & Greil, R 2020, 'Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial.', Journal of Clinical Medicine, vol. 9, no. 6. https://doi.org/10.3390/jcm9061663

Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial. / Rinnerthaler, Gabriel (First author); Gampenrieder, Simon Peter (First author); Hackl, Hubert et al.
In: Journal of Clinical Medicine, Vol. 9, No. 6, 2020.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial.

AU - Rinnerthaler, Gabriel

AU - Gampenrieder, Simon Peter

AU - Hackl, Hubert

AU - Steiner, Markus

AU - Monzo-Fuentes, Claudia

AU - Melchardt, Thomas

AU - Magnes, Teresa

AU - Huemer, Florian

AU - Westphal, Theresa

AU - Hufnagl, Clemens

AU - Hauser-Kronberger, Cornelia

AU - Egle, Alexander

AU - Greil, Richard

N1 - Rinnerhtaler; Gampenrieder; Steiner; Monzo-Fuentes; Melchardt; Magnes; Huemer; Westphal; Hufnagl; Egle; Greil: Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Department of Internal Medicine III with Haematology, Salzburg Cancer Research Institute, Oncologic Center Salzburg, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria; Hauser-Kronberger: Department of Pathology, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria

PY - 2020

Y1 - 2020

KW - PACLITAXEL PLUS BEVACIZUMAB

KW - PROGRESSION-FREE SURVIVAL

KW - 1ST-LINE BEVACIZUMAB

KW - GROWTH-FACTOR

KW - THERAPY

KW - HYPERTENSION

KW - CHEMOTHERAPY

KW - MICRORNAS

KW - SURROGATE

U2 - 10.3390/jcm9061663

DO - 10.3390/jcm9061663

M3 - Original Article

C2 - 32492882

SN - 2077-0383

VL - 9

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

IS - 6

ER -